Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

"A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients"

NCT03670888 is registered in ClinicalTrials.gov with JHL Biotech, Inc. as lead sponsor.

NCT NCT03670888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03670888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
"A Multicenter, Randomized, Double-blind, Parallel-controlled Trial to Compare the Bioequivalence and Safety of the Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody Injection (JHL1101) and Rituximab Injection in CD20 Positive B Cell Lymphoma Patients"
Lead sponsor
JHL Biotech, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
November 16, 2018
Completion date
March 19, 2019
Enrollment
1 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma